氯贝丁酯，1G，C6643-1G，Sigma

Application

Clofibrate has been used:

• as a quinolinate phosphoribosyltransferase (QPRT) agonist to study its effects on hepatitis C virus (HCV) infection
• as peroxisome proliferated activated receptor (PPAR) agonist to study its effects on autophagy in rat liver cells
• as a hepatotoxicant to study its effects on gene expression in primary rat hepatocytes

Biochem/physiol Actions

Clofibrate is a peroxisome proliferated activated receptor α (PPARα) agonist. It is a fibric acid derivative and has a therapeutic effect on hypertriglyceridemia and hyperlipoproteinemia type III. Clofibrate participates in lowering the very-low-density lipoprotein (VLDL) and cholesterol levels in hyperlipoproteinemia type III patients. It facilitates the decrease of total serum bilirubin concentration in Gilbert′s syndrome.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Wyeth. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.